Sign In
Buy PBM
$3.17
-0.190 (-5.65%)
At Close: Jul 31, 2026
Curaechoice Selects CVS Caremark at its PBM
10:58am, Monday, 24'th Nov 2025
All Active Curaechoice Members and their Families Will Have Access to CVS Pharmacies Nationwide Starting January 1 All Active Curaechoice Members and their Families Will Have Access to CVS Pharmacies
Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets
07:00am, Thursday, 20'th Nov 2025
NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and iboga
Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs
07:00am, Wednesday, 12'th Nov 2025
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Psyence BioMed (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine thera
Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care
07:00am, Thursday, 06'th Nov 2025
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and iboga
Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment
07:00am, Monday, 03'rd Nov 2025
NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and Iboga
Arbli ™ is the first and only ready-to-use liquid formulation of losartan, eliminating the need for compounding while offering reduced dosing volume and extended room-temperature shelf life
SOUTHBOROUGH, Mass.--(BUSINESS WIRE)--nirvanaHealth, the first to deploy an integrated Payer and PBM platform across all departments, announces the launch of its digital Transaction-as-a-Service (TaaS
Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025
08:00am, Thursday, 28'th Aug 2025
NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing nature-derived psilocybin and iboga
Pacific Bay Warrant Extension Not Proceeding
04:41pm, Friday, 01'st Aug 2025
Vancouver, British Columbia--(Newsfile Corp. - August 1, 2025) - Reagan Glazier, President & CEO, Pacific Bay Minerals Ltd. (TSXV: PBM) ("Pacific Bay" or, the "Company") reports that the proposed exte
Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production
07:30am, Thursday, 31'st Jul 2025
NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”) is pleased to announce that its strategic partner, PsyLabs – a leader in
CVS Health's Caremark to Lead CalPERS' PBM Vision: What's at Stake?
09:36am, Friday, 18'th Jul 2025
CVS wins a major CalPERS deal as Caremark replaces OptumRx, backed by $250M in performance guarantees and drug cost controls.
PSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common Shares
05:00pm, Wednesday, 25'th Jun 2025
TORONTO, June 25, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psilocybin in mental
PSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common Shares
05:36pm, Wednesday, 18'th Jun 2025
TORONTO, June 18, 2025 (GLOBE NEWSWIRE) -- Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of nature-derived psilocybin in
Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025
08:30am, Wednesday, 18'th Jun 2025
Investors, Entrepreneurs, and Industry Experts to Convene at the Premier Psychedelic Science Business Forum hosted by Multidisciplinary Association for Psychedelic Studies (MAPS) Denver, Colorado--(Ne
Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing Requirements
08:00am, Tuesday, 17'th Jun 2025
New York, New York--(Newsfile Corp. - June 17, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced that it has received formal notification from the Nasda
